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ABSTRACT
OBJECTIVES The REPAIR (Right vEntricular remodeling in Pulmonary ArterIal hypeRtension) study evaluated the effect
of macitentan on right ventricular (RV) and hemodynamic outcomes in patients with pulmonary arterial hypertension
(PAH), using cardiac magnetic resonance (CMR) and right heart catheterization (RHC).
BACKGROUND RV failure is the primary cause of death in PAH. CMR is regarded as the most accurate noninvasive
method for assessing RV function and remodeling and CMR measures of RV function and structure are strongly prog-
nostic for survival in patients with PAH. Despite this, CMR is not routinely used in PAH clinical trials.
METHODS REPAIR was a 52-week, open-label, single-arm, multicenter, phase 4 study evaluating the effect of maci-
tentan 10 mg, with or without phosphodiesterase type-5 inhibition, on RV remodeling and function and cardiopulmonary
hemodynamics. Primary endpoints were change from baseline to week 26 in RV stroke volume, determined by CMR; and
pulmonary vascular resistance, determined by RHC. Efficacy measures were assessed for all patients with baseline and
week 26 data for both primary endpoints.
RESULTS At a prespecified interim analysis in 42 patients, both primary endpoints were met, enrollment was stopped,
and the study was declared positive. At final analysis (n ¼ 71), RV stroke volume increased by 12 mL (96% confidence
level: 8.4-15.6 mL; P < 0.0001) and pulmonary vascular resistance decreased by 38% (99% confidence level: 31%-44%;
P < 0.0001) at week 26. Significant positive changes were also observed in secondary and exploratory CMR (RV and left
ventricular), hemodynamic, and functional endpoints at week 26. Improvements in CMR RV and left ventricular variables
and functional parameters were maintained at week 52. Safety (n ¼ 87) was consistent with previous clinical trials.
CONCLUSIONS In the context of this study, macitentan treatment in patients with PAH resulted in significant and
clinically-relevant improvements in RV function and structure and cardiopulmonary hemodynamics. At 52 weeks, im-
provements in RV function and structure were sustained. (REPAIR: Right vEntricular remodeling in Pulmonary ArterIal
hypeRtension [REPAIR]; NCT02310672) (J Am Coll Cardiol Img 2021;-:-–-) © 2021 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ISSN 1936-878X https://doi.org/10.1016/j.jcmg.2021.07.027
From the aAmsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; bDavid Geffen School of Medicine at
UCLA, Los Angeles, California, USA; cActelion Pharmaceuticals Ltd, Allschwil, Switzerland; dSheffield Pulmonary Vascular
Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom; eAlmazov National Medical Research Centre, St.
Petersburg, Russia; fScottish Pulmonary Vascular Unit, Glasgow, United Kingdom; gDepartment of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; hMassachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts, USA; iDepartment of Pulmonary Circulation, Thromboembolic Diseases and Cardiology,
Centre of Postgraduate Medical Education, ECZ-Otwock, Otwock, Poland; jDepartment of Cardiology, Heart Center at the
University of Cologne, and Cologne Cardiovascular Research Center (CCRC), Cologne, Germany; and the kDepartment of
Experimental, Diagnostic and Specialty Medicine–DIMES, University of Bologna, Bologna, Italy. *Current address: Roche,
Switzerland. yCo-last authors.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . - , N O . - , 2 0 2 1
ª 2 0 2 1 T H E A U T HO R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F OU N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
M
ost deaths in pulmonary arterial
hypertension (PAH) patients
result from failure of the right
ventricle (RV) (1). One defining feature of
PAH is increased pulmonary vascular resis-
tance (PVR), which results from obstructive
remodeling of the pulmonary vasculature
(1). In response to this elevated afterload, hy-
pertrophy of the RV occurs as a compensatory
mechanism to enhance contractility (1). For a
time, this adaptive remodeling maintains key
measures of cardiac function such as cardiac
index; however, sustained pressure overload
causes maladaptive remodeling, character-
ized by RV dilation, septal bowing, and
impaired contractility (1). Consequently, car-
diac index and right ventricular stroke vol-
ume (RVSV) begin to decrease, reflecting a
decline in RV function that eventually results
in RV failure and death (1). As such, reversing
this maladaptive remodeling and maintain-
ing RV function are important treatment
goals in PAH. Beneficial RV remodeling, indi-
cated by reduced RV mass and volume, has
been observed in patients with PAH undergoing lung
transplantation (2), and improvements in right heart
function have also been noted following pulmonary
endarterectomy in chronic thromboembolic pulmo-
nary hypertension patients (3). Beneficial RV remod-
eling has additionally been reported in patients with
PAH receiving PAH-targeted therapies (4-6).
Cardiac magnetic resonance (CMR) can provide
detailed information relating to RV function and
structure (7). It is regarded as the most accurate
noninvasive method for assessing RV function and
remodeling and provides complementary information
to right heart catheterization (RHC) (7). Previous
studies have demonstrated that CMR measures of RV
function and structure, including RVSV index, right
ventricular ejection fraction (RVEF), and right ven-
tricular end-systolic volume (RVESV), are strongly
prognostic for survival in patients with PAH (5,7-10),
can improve risk stratification for mortality of pa-
tients with PAH (7), and may predict clinical wors-
ening (10). Currently RVSV is the only RV CMR
endpoint with a published threshold for clinically-
relevant changes in PAH (11). CMR can also be used
to measure changes in RV function and structure in
response to therapy; in 91 patients with pulmonary
hypertension, the EURO-MR (European Magnetic
Resonance Imaging Study in PAH) study reported by
Peacock et al (5) described significant improvements
in CMR-assessed RVSV and RVEF after 12 months of
PAH-targeted therapy. Furthermore, a study of 24
patients by Hassoun et al (6) with scleroderma-
associated PAH showed significant improvements in
CMR-assessed RV mass and RVEF after 36 weeks of
treatment with ambrisentan and tadalafil (6). Despite
this, CMR is not routinely used in PAH clinical trials.
Macitentan, an oral, dual endothelin receptor
antagonist (ERA) approved for the long-term treat-
ment of PAH, is recommended for use as mono-
therapy or combination therapy (12,13). In the pivotal
SERAPHIN (Study with an Endothelin Receptor
Antagonist in Pulmonary Arterial Hypertension to
Improve Clinical Outcome) trial, once daily maci-
tentan 10 mg reduced the risk of the composite
morbidity/mortality primary endpoint by 45%
compared with placebo (12). In addition, after
6 months of treatment, there was a significant
decrease in PVR with cardiac index significantly
increasing, indicating beneficial hemodynamic ef-
fects (14). Macitentan has also been shown to prevent
maladaptive RV remodeling in animal models (15).
The significant delay in disease progression and
significantly reduced PVR shown in the SERAPHIN
study suggests that macitentan treatment has a
beneficial impact on RV function and structure.
The REPAIR (Right vEntricular remodeling in Pul-
monary ArterIal hypeRtension) study aimed to eval-
uate the effect of macitentan on RV and
hemodynamic outcomes in patients with symptom-
atic PAH, using CMR and RHC.
METHODS
STUDY DESIGN. REPAIR (NCT02310672) was a pro-
spective, multicenter, single-arm, open-label,
52-week, phase 4 study (Supplemental Figure 1,
Supplemental Table 1). Treatment with open-label
macitentan 10 mg was initiated on day 1 and
continued until week 52 (7 days) or premature
ABBR EV I A T I ON S
AND ACRONYMS
6MWD = 6-minute walk
distance
CMR = cardiac magnetic
resonance
ERA = endothelin receptor
antagonist
NT-proBNP = N-terminal pro–
B-type natriuretic peptide




PVR = pulmonary vascular
resistance
RHC = right heart
catheterization
RV = right ventricle
RVEF = right ventricular
ejection fraction
RVSV = right ventricular stroke
volume
WHO FC = World Health
Organization functional class
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discontinuation of the study drug. Physicians had the
option to additionally initiate phosphodiesterase
type-5 inhibitor (PDE-5i) within the first 14 days of
study drug treatment, in accordance with European
Society of Cardiology/European Respiratory Society
guidelines and recommendations from the Pro-
ceedings of the 6th World Symposium on Pulmonary
Hypertension (16-18). Per protocol, initiation of
rescue therapy prior to week 26 was permitted only in
the event of disease progression, defined as any of the
following: a decrease in 6-minute walk distance
(6MWD) of more than 15%, associated with worsening
in World Health Organization Functional Class (WHO
FC); the need for subcutaneous or intravenous pros-
tanoid therapy; or hospitalization for PAH. Initiation
of rescue therapy did not require discontinuation of
macitentan treatment. After week 26 RHC, treatment
changes were permitted.
PATIENT POPULATION. Eligible patients were 18-74
years of age with idiopathic or heritable PAH; PAH
related to connective tissue disease, drug use, or
toxin exposure; or simple congenital systemic-to-
pulmonary shunts at least 2 years after repair. RHC
was required for confirmation of the diagnosis. At
screening, patients were required to be PAH treat-
ment-naïve or receiving a stable background PDE-5i
for at least 3 months, have a 6MWD of $150 m, and
be in WHO FC I-III. Full inclusion/exclusion criteria
are available in the Supplemental Methods.
CLINICAL ASSESSMENTS. CMR was performed at
screening, week 26, and week 52. At interim analysis,
baseline and week 26 images were assessed for the
first 42 patients with available data. CMR was per-
formed using short-axis electrocardiographic (ECG)-
gated steady-state free precession imaging with
6-mm slice thickness and at least 25 temporal phases.
ECG-gated pulmonary arterial flow analysis was per-
formed in an imaging plane orthogonal to the main
pulmonary artery with a slice thickness of 6 to 8 mm,
and with velocity encoding at 120 cm/s. No infolding
FIGURE 1 Patient Disposition
Discontinued after Week 26 assessment† and prior to
Week 52 assessment‡: 5
2 PI decision − both AEs of AST increase
1 protocol criterion − AE of ALT and AST >3xULN
2 patient decision − 1 participate in other research; 1 refusal of any treatment
Discontinued after Week 52 assessment‡: 1
1 protocol criterion − AE of ALT and AST >3xULN
Discontinued prior to Week 26 assessment: 4
1 death − cardiac arrest
1 protocol criterion − AE of ALT and AST >3xULN
1 PI decision − AE of hypersensitivity
1 patient decision − tolerability due to edema
Missing Week 26 RVSV and/or PVR: 6
Missing baseline RVSV and/or PVR: 6
112 Screened*
Safety Set
87 patients received ≥1 dose
macitentan
Final Analysis Set
71 patients with both RVSV and PVR
measures at baseline and Week 26
66 patients in the Final Analysis Set
had Week-52 assessments
*For patients who screen failed, the most common inclusion criterion not met was the hemodynamic diagnosis of PAH, confirmed by RHC; the
most common exclusion criteria met was related to the presence of moderate to severe restrictive lung disease or signs of relevant lung
disease at screening. One patient who screen failed had "claustrophobia" reported. Two patients who screen failed had "atrial fibrillation,
multiple premature ventricular or atrial contractions, or any other condition that would interfere with proper cardiac gating during MRI"
reported. †Week 26 RHC and CMR assessments could be performed between weeks 16 and 30. ‡Week 52 assessments could be performed
between weeks 42 and 62. AE ¼ adverse event; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BL ¼ baseline;
CMR ¼ cardiac magnetic resonance; PI ¼ principal investigator; PVR ¼ pulmonary vascular resistance; RHC ¼ right heart
catheterization; RVSV ¼ right ventricular stroke volume; ULN ¼ upper limit of normal.
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artefacts or aliasing of images were allowed. Addi-
tional details of the CMR protocol are included in the
Supplemental Appendix.
For the final analysis, all images for a given patient
were analyzed at the same time by the same assessor,
blinded to patient identity and date of image acqui-
sition. Pulmonary artery flow imaging was used to
measure RVSV to ensure reliable measurement of the
blood volume going to the lungs. Assessment of PVR
was performed by RHC at screening and week 26, and
6MWD, WHO FC, and N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) were assessed at
screening, week 26, and week 52. Analysis of plasma
NT-proBNP was performed at a central laboratory.
OUTCOME MEASURES. The 2 primary endpoints
were assessed at week 26: change in RVSV from
baseline, as assessed by CMR (determined from pul-
monary artery flow); and change in PVR from base-
line, as assessed by RHC and expressed as the week 26
to baseline ratio. Secondary endpoints included
change from baseline to week 26 in: RVEF (deter-
mined from pulmonary artery flow), RV end-diastolic
volume, RVESV, and RV mass, measured by CMR;
6MWD; and WHO FC. Main exploratory endpoints
included change from baseline to week 26 in: mean
pulmonary arterial pressure (mPAP), mean right atrial
pressure and cardiac index, assessed by RHC; left
ventricular (LV) stroke volume (determined from
aortic flow), left ventricular end-diastolic volume
(LVEDV), LV end-systolic volume, LV ejection frac-
tion (determined from aortic flow), and LV mass,
assessed by CMR; and NT-proBNP. All endpoints
(excluding variables assessed by RHC) were repeated
at week 52 as exploratory endpoints. Adverse events
(AEs), serious adverse events (SAEs) (defined in the
Supplemental Appendix) and abnormal results from
laboratory studies were monitored until 30 days after
study drug discontinuation.
ANALYSIS SETS. The modified full analysis set (final
analysis set) comprised all enrolled patients who
received at least 1 dose of macitentan and had valid
measurements for both primary endpoints at baseline
and at week 26; the interim analysis set comprised the
first 42 patients meeting these criteria. Primary effi-
cacy analyses were performed using the interim and
final analysis sets; secondary and exploratory efficacy
analyses were performed using the final analysis set.
The safety set comprised all screened patients who
received at least one dose of macitentan.
STATISTICAL ANALYSES. The total sample size
(n ¼ 100) was based on the assumptions of an 8-mL
increase in RVSV from baseline to week 26, an 18%
decrease in PVR from baseline to week 26 (geometric
mean for ratio of baseline ¼ 0.82), an overall type I
error a ¼ 0.05 (2-sided) split unequally between the 2
primary endpoints RVSV (a ¼ 0.04) and PVR
(a ¼ 0.01), 90% power, and a protocol-specified
interim analysis performed on the first 42 patients
with assessments for both primary endpoints at week
26. The interim analysis used a hierarchical testing
approach, whereby if the change from baseline to
week 26 in RVSV was positive, the change in PVR
would be assessed. If both tests were positive, patient
enrollment was to be stopped and the study declared
positive. If either test was negative, patient accrual
was to continue until 100 patients were enrolled
(Supplemental Table 1). For the primary endpoints,
change from baseline in RVSV was analyzed using
analysis of covariance (ANCOVA) (96% confidence
level [CL]) with a factor for PAH-targeted therapy
(macitentan initiated alone in treatment-naïve pa-
tients, on top of stable background PDE-5i, or as
initial combination with a PDE-5i) and a covariate for
baseline RVSV. The ratio of week 26 vs baseline PVR
was log-transformed and analyzed using ANCOVA
(99% CL) with a factor for PAH-targeted therapy and a
covariate for baseline log PVR.
TABLE 1 Demographics and Baseline Disease Characteristics of Final




Age, y 45 (19, 71)
Age at PAH diagnosis, y 40 (18, 71)
Time from PAH diagnosis to screening, y 2  4
BMI, kg/m2 25.3  4.7
PAH etiology
Idiopathic PAH 42 (59.2)
Heritable PAH 2 (2.8)
Drug and toxin-induced 2 (2.8)
PAH associated with congenital heart diseasesa 5 (7.0)
PAH associated with connective tissue disease 20 (28.2)




6MWD at baseline, m 411.2  120.5
Treatment strategy
Macitentan initiated in treatment-naïve patients as
initial combination therapy with a PDE-5i
27 (38.0)
Macitentan initiated alone 44 (62.0)
In treatment-naïve patients 17 (23.9)
In patients receiving stable background
PDE-5i
27 (38.0)
Values are n (%), median (min, max), or mean  SD, unless otherwise indicated. aOnly simple
congenital systemic to pulmonary shunts at least 2 y post-surgical repair.
6MWD ¼ 6-minute walk distance; BMI ¼ body mass index; PAH ¼ pulmonary arterial hyper-
tension; PDE-5i ¼ phosphodiesterase-type 5 inhibitor; WHO FC ¼ World Health Organization
functional class.
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Primary endpoints were also analyzed for the
following subgroups using the ANCOVA models
specified for the main analysis: PAH-targeted treat-
ment strategy, WHO FC category at baseline (I/II vs
III/IV), sex (male vs female), and age (<65 years
vs $65 years).
Secondary and exploratory variables measured by
CMR and RHC were summarized and analyzed as
described for RVSV, using 95% CL. Change from
baseline in 6MWD was analyzed by ANCOVA with a
factor for PAH-targeted therapy and a covariate for
baseline 6MWD and WHO FC, using 95% CL.
Changes from baseline in WHO FC were dichoto-
mized as worsening vs no change or improvement,
with worsening analyzed using a logistic regression
model with a factor for PAH-targeted therapy at
baseline, using 95% CL. Change from baseline in
NT-proBNP was analyzed as described for PVR, us-
ing 95% CL.
Secondary and exploratory efficacy analyses were
performed with no correction for multiple testing;
thus, all analyses are of an exploratory nature.
For all endpoints, analyses were based on observed
data, and no imputations for missing data were per-
formed. Images were assessed by independent im-
aging specialists, blinded to the patient identity and
to the date and the time point of image acquisition.
MONITORING AND ETHICS STATEMENT. The study
was designed by the Steering Committee in conjunc-
tion with the sponsor (Actelion Pharmaceuticals Ltd,
a Janssen Pharmaceutical Company of Johnson &
Johnson). Ethical approval was received from inde-
pendent ethics committees/institutional review
boards, and the study was conducted in compliance
with the Declaration of Helsinki. Written informed
consent was obtained from all patients. CMR and
echocardiography results were assessed by a blinded
central imaging committee.
RESULTS
PATIENT DISPOSITION AND INTERIM ANALYSIS.
Patients were screened at 29 sites across 11 countries,
with the protocol-specified interim analysis per-
formed when both baseline and week 26 RVSV and
PVR measurements were available for 42 patients
(interim analysis set). As both primary endpoints
were met, the study was declared positive and
enrollment was stopped.
At cessation of enrollment, 112 patients had been
screened with 87 patients receiving at least 1 dose of
macitentan (safety set). The 71 patients with both
baseline and week 26 PVR and RVSV measurements
comprised the final analysis set (Figure 1). Reasons for


















































































































In Treatment Naive Patients
In Patients Receiving Stable Background PDE-5i
In Treatment Naïve Patients as Initial Combination With a PDE-5i
CL ¼ confidence limit; FC ¼ functional class; PDE-5i ¼ phosphodiesterase type-5 inhibitor; other abbreviations as in Figure 1.
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patient exclusion from the final analysis set are
shown in Supplemental Table 2. Patients with treat-
ment changes during the study included 6 (6.9%)
before and 8 (9.2%) after week 26 (Supplemental
Table 3).
DEMOGRAPHICS AND BASELINE CHARACTERISTICS.
Patients in the final analysis set had a median age of
45 years (range 19-71 years) at baseline, 80.3% were
women, and 59.2% had idiopathic PAH. For these
patients, mean  SD 6MWD was 411.2  120.5 m, and
most were in WHO FC II (47.9%) or III (50.7%) at
baseline (Table 1). Macitentan was initiated as mon-
otherapy in 23.9% of patients, on top of stable back-
ground PDE-5i therapy in 38.0% of patients, and
simultaneously with a PDE-5i in 38.0% of patients.
Time from diagnosis to screening across the
final analysis set, to the nearest year, is shown in
Supplemental Table 4. Demographics and baseline
characteristics for the interim analysis and safety sets
are presented in Supplemental Table 5.
PRIMARY EFFICACY ENDPOINTS. For the primary
efficacy endpoints, at final analysis (n ¼ 71), mean
RVSV increased from baseline to week 26 by 12.0 mL
(96% CL: 8.4-15.6 mL; P < 0.0001) and PVR decreased
by 38% from baseline to week 26 (model-adjusted
geometric mean ratio: 0.62 [99% CL: 0.56-0.69; P <
0.0001]) (Figure 2, Table 2), confirming the positive
results of the interim analysis (n ¼ 42), where mean
RVSV increased from baseline to week 26 by 15.2 mL
(96% CL: 9.3-21.0 mL; P < 0.0001), and PVR decreased
by 37% from baseline to week 26 (model-adjusted
geometric mean ratio 0.63 [99% CL: 0.54-0.74; P <
0.0001]) (Table 2).
SUBGROUP ANALYSIS. Subgroup analyses (Figure 3)
of the final analysis set demonstrated that the treat-
ment effects for RVSV and PVR were generally
consistent with the overall effect for all subgroups,
with the exception of treatment strategy, for which
the largest treatment effect was seen in treatment-
naïve patients initiating macitentan in combination
with a PDE-5i. As the study was not powered for tests
in these subgroups, such results should be inter-
preted with caution.
OTHER EFFICACY ENDPOINTS (SECONDARY AND
EXPLORATORY). In addition to RVSV, significant
improvements from baseline to week 26 were
observed in the CMR secondary endpoints of RVESV,
RVEF, and RV mass, and in the exploratory endpoints
of LV stroke volume, LVEDV, LV ejection fraction, LV
mass, and the RV/LV diastolic and systolic volume
ratios (Table 3). Example CMR images from a female
patient who received initial combination therapy
with macitentan and a PDE-5i are shown in Figure 4.
The improvements observed in these variables at
week 26 were maintained and significant at week 52
(Table 3).
With respect to the change from baseline to week
26 in the exploratory hemodynamic endpoints, sig-
nificant improvements were observed for mPAP
(mean decrease of 7.7 mm Hg [95% CL: 10.0
to 5.4 mm Hg]) and cardiac index (mean increase of
0.5 L/min/m2 [95% CL: 0.4-0.7 L/min/m2]); mean
right atrial pressure was not changed (Table 4).
Patients’ 6MWD (n ¼ 71) significantly increased
from baseline to week 26 by a mean of 35.6 m (95%
CL: 19-52 m), and this change was maintained at week
52 (mean increase of 38.2 m [95% CL: 19-57 m]; n ¼ 65)
(Table 4). Furthermore, at week 26, the majority
(57.1%) of patients had improved WHO FC (n ¼ 70)
and no patients had worsened (1 patient had missing
data) (Table 4). Similar results were observed at week
52 (n ¼ 65; 52.3% of patients had improved; no pa-
tients had worsened) (Table 4).
Finally, NT-proBNP levels significantly decreased
by 55% (95% CL: 46%-63%) (absolute
change 425.1 ng/L [95% CL: 650.2 to 200.1 ng/L];
n ¼ 60) from baseline to week 26, and this was
maintained at Week 52 (decrease of 56% [95% CL:
TABLE 2 Primary Endpoints of Change From Baseline to Week 26 in RVSV and PVR
Interim Analysis Set (n ¼ 42) Final Analysis Set (n ¼ 71)
Baseline
Change From Baseline to Week 26a
LS Mean (96% CL) P Value Baseline
Change From Baseline to Week 26a
LS Mean (96% CL) P Value
RVSV, mL 50.7  17.5 15.2 (9.3-21.0) <0.0001c 52.2  17.2 12.0 (8.4-15.6) <0.0001c
Baseline
Week 26/Baseline Ratiob
Geometric Mean (99% CL) P Value Baseline
Week 26/Baseline Ratiob
Geometric Mean (99% CL) P Value
PVR, dyns/cm5 900.2  457.6 0.63 (0.54-0.74) <0.0001c 974.6  679.0 0.62 (0.56-0.69) <0.0001c
Baseline values are mean  SD. aAdjusted change using an analysis of covariance model with a factor for PAH-targeted background therapy and a covariate for baseline
parameter value. bAdjusted change using an analysis of covariance model with a factor for PAH-targeted background therapy and a covariate for baseline log PVR. c2-sided P
value.
CL ¼ confidence limit; LS ¼ least squares; PVR ¼ pulmonary vascular resistance; RVSV ¼ right ventricular stroke volume.
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FIGURE 3 Subgroup Analysis of Change From Baseline to Week 26 in RVSV and PVR in the Final Analysis Set (n ¼ 71)
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(P-Value = 0.0471)
PAH Background Therapy







Macitentan Initiated Alone Either in Treatment Naive Patients or
Patients Receiving Stable Background PDE-5i
Macitentan Initiated in Treatment Naive Patients as Initial
Combination With a PDE-5i
Macitentan 10 mg
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Baseline 99% CL n (trt)
0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
n(trt) ¼ number of patients receiving macitentan; WHO FC ¼ World Health Organization functional class; other abbreviations as in Figures 1
and 2.
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47%-64%]; absolute change 484.2 ng/L [95%
CL: 692.1 to 276.3 ng/L]; n ¼ 57) (Table 4).
SAFETY AND TOLERABILITY. Safety and tolerability
were assessed in the safety set (n ¼ 87). Median (min,
max) exposure time was 52.0 weeks (1.1, 58.3 weeks)
(Table 5). There were 75 (86.2%) patients who re-
ported at least 1 AE and 14 (16.1%) patients reported at
least 1 SAE (Table 5, Supplemental Table 6). The most
frequent AEs ($20% of patients) were peripheral
edema (n ¼ 19, 21.8%) and headache (n ¼ 18, 20.7%).
For 26 (29.9%) patients, at least 1 treatment-emergent
AE relating to edema and fluid retention was re-
ported; 17 (19.5%) patients had at least 1 treatment-
emergent AE relating to anemia (Supplemental
Table 7); and 3 (3.5%) patients had hemoglobin de-
creases to #80 g/L (Supplemental Table 8).
There were 10 (11.5%) patients who discontinued
macitentan treatment; 1 (1.1%) patient died, 3 (3.4%)
patients discontinued because of meeting pre-
specified discontinuation criteria, 3 (3.4%) patients
discontinued because of physician’s decision, and 3
(3.4%) patients discontinued because of patient de-
cision. The 1 death recorded was the result of a fatal
SAE of cardiac arrest, which occurred after the patient
experienced a pulmonary embolism (Figure 1). Labo-
ratory abnormalities of alanine aminotransferase/
aspartate aminotransferase $3 the upper limit of
normal were reported for 5 (5.8%) patients in the
safety set (Supplemental Table 8).
DISCUSSION
MACITENTAN IMPROVES RV FUNCTION AND
STRUCTURE AS DETERMINED BY CMR AND
HEMODYNAMIC PARAMETERS. REPAIR is one of the
largest multicenter clinical trials in PAH to use a CMR
variable as a primary endpoint. Here we show that
macitentan treatment, alone or in combination with a
PDE-5i, led to statistically significant and clinically
relevant improvements in RVSV (11) and PVR at week
26, with improvements in RVSV maintained at week
52 (Central Illustration). Improvements were also seen
in the majority of the secondary and exploratory CMR
(RV and LV variables and the RV/LV volumetric ra-
tios), hemodynamic, and functional endpoints.
Improving RV function and structure is key to
improving outcomes in patients with PAH. In REPAIR,
the observed improvements in RVSV brought the
mean to within the normal range (ie, between the 5th
and 95th percentile in men [63-122 mL] and women
[50-95 mL]) (19). This improvement was mirrored in
the significant changes of RVEF and RVESV, both of
which are strongly prognostic in PAH (7,20). That
beneficial changes were observed for both RV func-
tion (RVSV and RVEF) and structure (RVESV and RV
TABLE 3 Change From Baseline to Weeks 26 and 52 in Primary, Secondary, and Exploratory CMR Endpoints in the Final Analysis Set (n ¼ 71)
Parameter
Week 26 Week 52
n Baseline
Change From Baseline to Week 26a
LS Mean (95% CL) P Value n Baseline
Change From Baseline to Week 52a
LS Mean (95% CL) P Value
Primary Endpoint Exploratory Endpoint
RVSV, mL 71 52.2  17.2 12.0 (8.4 to 15.6)b <0.0001 63 52.2  17.1 12.0 (8.4 to 15.6) <0.0001
Secondary Endpoints Exploratory Endpoints
RV end-diastolic volume, mL 70 149.8  49.1 6.2 (12.8 to 0.4) ns 63 149.3  47.8 5.3 (12.0 to 1.4) ns
RV end-systolic volume, mL 70 90.2  40.6 16.1 (20.0 to 12.2) <0.0001 63 89.2  38.1 17.0 (22.1 to 12.0) <0.0001
RVEF,c % 70 37.7  14.3 10.6 (7.9 to 13.3) <0.0001 62 37.9  14.2 9.5 (7.0 to 12.0) <0.0001
RV mass, g 70 110.4  47.5 10.5 (14.0 to 7.1) <0.0001 63 111.0  49.1 9.2 (12.9 to 5.5) <0.0001
Exploratory Endpoints Exploratory Endpoints
LV stroke volume,d mL 67 47.5  14.0 13.8 (10.7 to 16.9) <0.0001 61 47.5  14.4 13.8 (10.5 to 17.0) <0.0001
LV end-diastolic volume, mL 70 87.2  29.1 17.4 (12.4 to 22.5) <0.0001 63 88.1  30.0 17.0 (12.7 to 21.4) <0.0001
LV end-systolic volume, mL 70 32.2  16.1 1.7 (1.0 to 4.4) ns 63 32.7  16.0 3.1 (0.6 to 5.6) <0.05
LV ejection fraction,d % 66 56.3  10.5 3.6 (1.1 to 6.1) <0.01 61 55.9  10.4 4.5 (2.0 to 7.0) <0.001
LV mass, g 70 103.4  23.7 3.8 (1.4 to 6.2) <0.01 63 103.6  24.6 4.0 (1.1 to 7.0) <0.01
Exploratory Endpoints Exploratory Endpoints
n Baseline
Geometric Means Ratio of
Week 26 to Baselinee (95% CL) P Value n Baseline
Geometric Means Ratio of
Week 52 to Baselinee (95% CL) P Value
RV/LV end-diastolic volume 70 1.8  0.65 0.79 (0.76 to 0.83) <0.0001 63 1.8  0.65 0.80 (0.77 to 0.84) <0.0001
RV/LV end-systolic volume 70 3.2  1.62 0.78 (0.73 to 0.83) <0.0001 63 3.1  1.64 0.73 (0.67 to 0.80) <0.0001
Baseline values are mean  SD. aAnalyzed using an analysis of covariance with a factor for PAH-targeted background therapy and a covariate for baseline parameter value. b96% CL. cFrom pulmonary artery
flow. dFrom aortic flow. eFrom analysis of covariance model on log-transformed change ratio with baseline ratio as a covariate.
LV ¼ left ventricular; ns ¼ not significant; RV ¼ right ventricular; RVEF ¼ right ventricular ejection fraction; other abbreviations as in Table 2.
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mass) suggests that macitentan contributes to bene-
ficial remodeling of the RV in patients with PAH. In
addition, significant improvements were observed for
LV CMR variables, including LVEDV, which has been
shown to have prognostic value in PAH (7). Together,
these results suggest that macitentan-related im-
provements in RV structure and function are associ-
ated with improvements in LV function.
The REPAIR study showed that macitentan treat-
ment also improved hemodynamic parameters with
significant reductions in PVR, mPAP and an increase
in cardiac index. This is consistent with previous
studies reporting that macitentan significantly im-
proves hemodynamics irrespective of WHO FC and
background PAH-targeted therapy (12,14). Whether
macitentan’s effects on hemodynamics and RV
structure are mechanistically linked remains unclear.
The reduction in PVR induced by macitentan may
indirectly lead to reverse remodeling of the RV by
improving cardiac function; however, in vivo studies
conducted in rats have also revealed that expression
of genes related to RV remodeling are reduced after
treatment with macitentan (15), suggesting a direct
effect on RV structure.
FIGURE 4 Example of RV (and LV) Changes in 1 Patient at Screening (End Systole) and Week 26 (End Systole)



























Images from a 49-year-old female who received initial combination therapy with macitentan and a phosphodiesterase-type 5 inhibitor at (A) screening (end systole)
and (B) week 26 (end systole). Changes over time: right ventricular (RV) size reduced (purple line), left ventricular (LV) size increased (green line), septal bowing shift
from left to right, reflecting pressure changes (white arrows). Slice position indicated by red line in the top panels.
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Patients who received macitentan as initial double
combination therapy with a PDE-5i had numerically
larger improvements than those initiating macitentan
alone (either as monotherapy or sequential combi-
nation therapy), supporting the treatment approach
recommended in the European Society of Cardiology/
European Respiratory Society guidelines (16,17).
However, there were major imbalances in baseline
characteristics between the initial treatment regimen
subgroups, and no formal statistical comparisons
have been performed.
MACITENTAN TREATMENT LEADS TO LONG-TERM
IMPROVEMENTS IN KEY CLINICAL PARAMETERS
Improvements were also seen in several key clinical
parameters in the REPAIR study; 6MWD signifi-
cantly increased from baseline to week 26, and the
majority of patients had an improvement in WHO
FC. In addition, NT-proBNP, a biomarker for cardiac
overload (21) and prognostic for PAH (22), was
significantly reduced. All of these improvements
were maintained at week 52, supporting a sustained
benefit of macitentan treatment beyond the
TABLE 4 Change From Baseline to Week 26 in Exploratory RHC Endpoints, and From Baseline to Weeks 26 and 52 in Secondary and Exploratory Functional




Change From Baseline to Week 26a
LS Mean (95% CL) P Value
Mean pulmonary arterial pressure, mm Hg 71 53.5  15.3 7.7 (10.0 to 5.4) <0.0001
Mean right atrial pressure, mm Hg 70 6.7  4.0 0.3 (1.1 to 0.5) ns
Cardiac index, L/min/m2 71 2.4  0.7 0.5 (0.4 to 0.7) <0.0001
Secondary Endpoints Exploratory Endpoints
n Baseline
Change From Baseline to Week 26b
LS Mean (95% CL) P Value n Baseline
Change From Baseline to Week 52b
LS Mean (95% CL) P Value
6MWD, m 71 411.2  120.5 35.6 (19.0 to 52.3) <0.0001 65 414.6  120.6 38.2 (19.0 to 57.4) <0.001
n Baseline Change From Baseline to Week 26 P Value n Baseline Change From Baseline to Week 52 P Value
WHO FC 70 FC I: 1 (1.4)
FC II: 34 (48.6)




NA 65 FC I: 1 (1.5)
FC II: 33 (50.8)





Exploratory Endpoints Exploratory Endpoints
n Baseline
Geometric Means Ratio of
Week 26 to Baselinec (95% CL) P Value n Baseline
Geometric Means Ratio of
Week 52 to Baselinec (95% CL) P Value
NT-proBNP, ng/L 60 846.7  1,006.7 0.45 (0.37 to 0.54) <0.0001 57 780.1  962.0 0.44 (0.36 to 0.53) <0.0001
Baseline values are n, mean  SD, or n (%). RHC assessments (mean pulmonary arterial pressure, mean right atrial pressure, cardiac index) were not performed at 52 wk. aFrom analysis of covariance
(ANCOVA) model on parameter change from baseline with a factor for PAH-targeted treatment strategy and parameter at baseline as a covariate. bFrom ANCOVA model on parameter change from baseline
with factors for PAH-targeted treatment strategy and baseline WHO FC, and parameter at baseline as a covariate. cFrom ANCOVA model on log-transformed N-terminal pro–B-type natriuretic peptide (NT-
proBNP), with a factor for PAH-targeted treatment strategy and baseline log NT-proBNP level as a covariate.
NA ¼ not applicable; other abbreviations as in Tables 2 and 3.
TABLE 5 Exposure and Overview of Safety
Safety Set (n ¼ 87)
Duration of study treatment, wk
Mean  SD 48.6  11.3
Median (min, max) 52.0 (1.1, 58.3)
Adverse events and serious adverse events
Patients with $1 treatment-emergent AE in $10% of patients 75 (86.2)




Hemoglobin decreased 10 (11.5)
Upper respiratory tract infection 10 (11.5)
Myalgia 9 (10.3)
Patients with $1 AE leading to discontinuation of study treatment 7 (8.0)
Aspartate aminotransferase increased 2 (2.3)
Transaminases increased 2 (2.3)
Hypersensitivity 1 (1.1)
Liver function test increased 1 (1.1)
Edema peripheral 1 (1.1)
Patients with $1 treatment-emergent SAE 14 (16.1)
Fatal TE serious AE 1 (1.1)
Values are n (%), unless otherwise indicated.
AE ¼ adverse event; SAE ¼ serious adverse event; TE ¼ treatment emergent.
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typical 6-month observation period of PAH clinical
studies.
The REPAIR study adds to the body of evidence
supporting the efficacy of macitentan in PAH pa-
tients, including those receiving initial double com-
bination therapy with macitentan and a PDE-5i (23),
and reports safety data consistent with the known
profile of macitentan (12,13).
CONSISTENT CMR RESULTS HIGHLIGHT THE CLINICAL
RELEVANCEOF THIS NONINVASIVE IMAGING TECHNIQUE.
RHC is the gold standard technique for measuring
pressure (mPAP and pulmonary capillary wedge
pressure) and calculating PVR (24). However, as the
procedure is invasive and carries a small risk of
complications, serial assessments are not routinely
performed in clinical practice. By contrast, CMR is
noninvasive, therefore lowering the risk for repeat
assessments (24). Although CMR is more expensive
and time-consuming than other noninvasive tech-
niques such as echocardiography, the superior
spatiotemporal resolution that CMR provides trans-
lates into an increased cost to benefit ratio (25). The
clinical and cost benefits of CMR, including in pa-
tients with PH, has been further explored by Hegde
et al (25).
As both REPAIR primary endpoints were positive
and consistent with changes in hemodynamic (mPAP
and cardiac index) and functional parameters
(6MWD, WHO FC), this study provides further confi-
dence in CMR-assessed endpoints and their potential
use in future trials. In addition, CMR metrics have
been shown to be reproducible, have prognostic
value, and aid risk stratification in patients with PAH
(5,7,26). The consistency of the CMR results pre-
sented here underline the clinical relevance of this
imaging modality as a reliable noninvasive technique
for monitoring disease status.
Previous studies in patients with PAH have used
CMR parameters as endpoints to assess the effects of
PH-targeted therapies on beneficial remodeling of the
RV (27-29). The SERAPH (Sildenafil versus Endothelin
Receptor Antagonist for Pulmonary Hypertension)
randomized controlled trial (29) and a prospective
observational study from van Wolferen et al (28)
CENTRAL ILLUSTRATION REPAIR: Effects of Treatment With Macitentan on Right Ventricular Remodeling in
Pulmonary Arterial Hypertension
REPAIR:
Effects of treatment with macitentan on right ventricular (RV) remodeling
in pulmonary arterial hypertension (PAH)
Treatment resulted in signicant and clinically relevant improvements in RVSV and PVR
A Prospective, Multicenter,

















LS mean change (99% CL), P value
(8.4, 15.6), P<0.0001
LS mean change (96% CL), P value
Primary Endpoints at Final Analysis
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REPAIR is the largest multicenter clinical trial in pulmonary arterial hypertension to use a cardiac magnetic resonance variable as a primary endpoint. Macitentan
treatment, alone or in combination with a phosphodiesterase-type 5 inhibitor, led to statistically significant and clinically relevant improvements in right ventricular
(RV) stroke volume and pulmonary vascular resistance at week 26, with improvements in RV stroke volume maintained at week 52.
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examined the addition of sildenafil to bosentan in
patients with PAH; both reported decreases in RV
mass of approximately 8-9 g with combination ther-
apy. More recently, Hassoun et al (6) reported that
combination therapy with ambrisentan and tadalafil
resulted in a significant reduction in RV mass in
treatment-naïve SSc-PAH patients (4.5 g). In contrast,
an earlier study from Roeleveld et al (30) did not
report significant changes in RV mass or RV end-
diastolic volume measured by CMR in patients with
PH treated with epoprostenol. Three clinical studies
have also reported significant improvements in RVEF
in patients with PH receiving PH-targeted therapies;
van Wolferen et al (28) and van de Veerdonk et al (23)
reported improvements following combination ther-
apy with an ERA and PDE-5i, and the EURO-MR study
(5) reported improvement with monotherapy (either
ERA or PDE-5i). The COMPASS-3 study also supported
the use of CMR in a clinical trial setting, with a
number of CMR parameters found to predict clinical
worsening/decline in patients with PAH (27). REPAIR
extends these findings by showing that improve-
ments were made for RV mass and RVEF in a multi-
regional PAH population receiving either macitentan
monotherapy or combination therapy.
STUDY LIMITATIONS. Limitations of this study
include its open-label design and the study size,
which limited subgroup analyses.
CONCLUSIONS
The REPAIR study provides robust data to support the
potential use of RVSV from CMR to assess RV cardiac
function in future clinical trials in PAH. In addition to
improving hemodynamic parameters (PVR, mPAP,
cardiac index), PAH treatment with macitentan as
monotherapy or part of combination therapy in this
study resulted in improved RV function and struc-
ture, as shown by clinically relevant changes in CMR-
measured RVSV, RVESV, RV mass, and RVEF, and in
the corresponding LV parameters. Macitentan safety
and tolerability were consistent with previous clinical
trial data.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
REPAIR study provides evidence that macitentan treat-
ment significantly improves RV function and structure in
patients with PAH, including those receiving initial double
combination therapy with a PDE-5i. That these improve-
ments were maintained for up to 52 weeks further sup-
ports the use of macitentan in PAH.
TRANSLATIONAL OUTLOOK: The consistent CMR
results reported here, and in other studies, underscore
the clinical relevance of this noninvasive imaging tech-
nique in monitoring PAH disease status and progression,
and provide further confidence in CMR-assessed end-
points and their potential use in future trials.
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APPENDIX For an expanded Methods section
as well as a supplemental figure and tables,
please see the online version of this paper.
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